Ken Griffin Igm Biosciences, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 10,000 shares of IGMS stock, worth $68,700. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,000

Previous 11,100 9.91%

Holding current value

$68,700

Previous $92,000 4.35%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.68 - $17.36 $1.72 Million - $3.44 Million	-198,345 Reduced 93.78%	13,163 $127,000
Q4 2023 Feb 14, 2024	BUY	$3.94 - $8.79 $759,064 - $1.69 Million	192,656 Added 1021.94%	211,508 $1.76 Million
Q3 2023 Nov 14, 2023	SELL	$6.66 - $10.64 $41,971 - $67,053	-6,302 Reduced 25.05%	18,852 $157,000
Q2 2023 Aug 14, 2023	BUY	$8.86 - $14.0 $171,697 - $271,306	19,379 Added 335.57%	25,154 $232,000
Q1 2023 May 15, 2023	SELL	$13.74 - $25.76 $193,651 - $363,061	-14,094 Reduced 70.93%	5,775 $79,000

Q4 2022 Feb 14, 2023	SELL	$15.45 - $26.02 $27,887 - $46,966	-1,805 Reduced 8.33%	19,869 $337,000
Q3 2022 Nov 14, 2022	SELL	$15.42 - $27.01 $35,620 - $62,393	-2,310 Reduced 9.63%	21,674 $493,000
Q2 2022 Aug 15, 2022	SELL	$13.27 - $25.5 $390,774 - $750,924	-29,448 Reduced 55.11%	23,984 $432,000
Q1 2022 May 16, 2022	BUY	$13.42 - $29.73 $123,893 - $274,467	9,232 Added 20.89%	53,432 $1.43 Million
Q3 2021 Nov 15, 2021	SELL	$65.76 - $90.65 $217,928 - $300,414	-3,314 Reduced 6.97%	44,200 $2.91 Million
Q1 2021 May 17, 2021	BUY	$71.56 - $121.23 $333,111 - $564,325	4,655 Added 10.86%	47,514 $3.64 Million
Q4 2020 Feb 16, 2021	BUY	$47.41 - $115.03 $444,326 - $1.08 Million	9,372 Added 27.99%	42,859 $3.78 Million
Q3 2020 Nov 16, 2020	BUY	$43.0 - $84.01 $459,154 - $897,058	10,678 Added 46.81%	33,487 $2.47 Million
Q2 2020 Aug 14, 2020	BUY	$51.3 - $75.21 $97,008 - $142,222	1,891 Added 9.04%	22,809 $1.67 Million
Q1 2020 May 15, 2020	BUY	$31.51 - $73.75 $226,619 - $530,410	7,192 Added 52.4%	20,918 $1.18 Million
Q4 2019 Feb 14, 2020	SELL	$17.25 - $49.51 $627,348 - $1.8 Million	-36,368 Reduced 72.6%	13,726 $524,000
Q3 2019 Nov 14, 2019	BUY	$17.75 - $24.3 $889,168 - $1.22 Million	50,094 New	50,094 $889,000

Others Institutions Holding IGMS

# of Institutions

Shares Held

20.5M

Call Options Held

11.1K

Put Options Held

5.1K

View Full List

About IGM Biosciences, Inc.

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $199M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

More about IGMS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account